• Print page
  • Bookmark Page

Announcements

Date Title PDF
20 October 2014 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 504KB, opens in a new window
9 October 2014 Recordati initiates a share buy-back program Recordati initiates a share buy-back program PDF, 499KB, opens in a new window
22 September 2014 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 139KB, opens in a new window
16 September 2014 Recordati obtains license to new treatment for premature ejaculation from Plethora Recordati obtains license to new treatment for premature ejaculation from Plethora PDF, 143KB, opens in a new window
29 July 2014 Notice of filing of First Half 2014 Notice of filing of First Half 2014 PDF, 122KB, opens in a new window
29 July 2014 Recordati reports excellent results in the first half 2014. Sales +6.3%, operating income +18.8% and net income +18.1 Recordati reports excellent results in the first half 2014. Sales +6.3%, operating income +18.8% and net income +18.1 PDF, 240KB, opens in a new window
3 July 2014 Recordati: Carbaglu® receives orphan drug designation in the U.S. For organic acidemias Recordati: Carbaglu® receives orphan drug designation in the U.S. For organic acidemias PDF, 155KB, opens in a new window
9 May 2014 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 139KB, opens in a new window
6 May 2014 Recordati: sales growth and significant margin improvement in the first quarter 2014 (sales +6.5%, operating income +18.1%, net income +13.2%) Recordati: sales growth and significant margin improvement in the first quarter 2014 (sales +6.5%, operating income +18.1%, net income +13.2%) PDF, 187KB, opens in a new window
6 May 2014 Notice of filing of First Quarter 2014 Notice of filing of First Quarter 2014 PDF, 74KB, opens in a new window
18 April 2014 Notice of 2013 final dividend payment Notice of 2013 final dividend payment PDF, 50KB, opens in a new window
17 April 2014 Recordati: Shareholders approve the 2013 accounts. Dividend € 0.33 per share. Recordati: Shareholders approve the 2013 accounts. Dividend € 0.33 per share. PDF, 192KB, opens in a new window
27 March 2014 Recordati: publication of lists of candidates for the appointment of Directors and Statutory Auditors of the company Recordati: publication of lists of candidates for the appointment of Directors and Statutory Auditors of the company PDF, 397KB, opens in a new window
24 March 2014 Recordati: notice pursuant to art. 144-octies, paragraph 2 of issuers' regulations Recordati: notice pursuant to art. 144-octies, paragraph 2 of issuers' regulations PDF, 397KB, opens in a new window
21 March 2014 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 391KB, opens in a new window
14 March 2014 Recordati: public disclosure compliance Recordati: public disclosure compliance   PDF, 392KB, opens in a new window
7 March 2014 Notice of filing of the 2013 Annual Report Notice of filing of the 2013 Annual Report PDF, 178KB, opens in a new window
6 March 2014 Recordati: Board approves the2013 accounts. Revenue € 941.6 million (+13.7%), operating income € 195.4 million (+17.0%), net income € 133.7 million (+12.8%). 2013 dividend € 0.33 (+10.0%) Recordati: Board approves the2013 accounts. Revenue € 941.6 million (+13.7%), operating income € 195.4 million (+17.0%), net income € 133.7 million (+12.8%). 2013 dividend € 0.33 (+10.0%) PDF, 208KB, opens in a new window
11 February 2014 Recordati: preliminary 2013 results show significant growth. Sales +13.7%, EBIT +17.0%, net income +12.8%. A productive year for investments Recordati: preliminary 2013 results show significant growth. Sales +13.7%, EBIT +17.0%, net income +12.8%. A productive year for investments  PDF, 176KB, opens in a new window
16 January 2014 Recordati Board of Directors approves 2014 objectives Recordati Board of Directors approves 2014 objectives PDF, 151KB, opens in a new window
31 October 2013 Recordati finalizes the first tranche of its acquisition of Opalia Pharma in Tunisia Recordati finalizes the first tranche of its acquisition of Opalia Pharma in Tunisia PDF, 141KB, opens in a new window
31 October 2013 Interim Report - First nine months 2013 and 2013 interim dividend payment Interim Report - First nine months 2013 and 2013 interim dividend payment PDF, 63KB, opens in a new window
30 October 2013 Recordati reports significant growth in the first nine months 2013. Sales +13.2%, operating income +12.0% and net income +9.0%. Interim dividend € 0.22 per share Recordati reports significant growth in the first nine months 2013. Sales +13.2%, operating income +12.0% and net income +9.0%. Interim dividend € 0.22 per share PDF, 281KB, opens in a new window
21 October 2013 Recordati finalizes its acquisition of Laboratorios Casen Fleet in Spain Recordati finalizes its acquisition of Laboratorios Casen Fleet in Spain PDF, 141KB, opens in a new window
18 October 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 406KB, opens in a new window
17 September 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program  PDF, 409KB, opens in a new window
9 September 2013 Recordati acquires the Spanish pharmaceutical company Laboratorios Casen Fleet Recordati acquires the Spanish pharmaceutical company Laboratorios Casen Fleet PDF, 143KB, opens in a new window
6 September 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program  PDF, 412KB, opens in a new window
26 July 2013 Notice of filing of First Half 2013 Notice of filing of First Half 2013 PDF, 50KB, opens in a new window
25 July 2013 Recordati reports excellent results in the first half 2013. Sales +13.8%, operating income +13.8% and net income +11.1% Recordati reports excellent results in the first half 2013. Sales +13.8%, operating income +13.8% and net income +11.1% PDF, 209KB, opens in a new window
24 July 2013 Recordati acquires the Tunisian pharmaceutical company Opalia Pharma Recordati acquires the Tunisian pharmaceutical company Opalia Pharma PDF, 142KB, opens in a new window
24 July 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 411KB, opens in a new window
3 July 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 409KB, opens in a new window
24 June 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 410KB, opens in a new window
14 June 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 412KB, opens in a new window
6 June 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 412KB, opens in a new window
29 May 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 411KB, opens in a new window
21 May 2013 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 408KB, opens in a new window
10 May 2013 Notice of filing of First Quarter 2013 Notice of filing of First Quarter 2013 PDF, 74KB, opens in a new window
9 May 2013 Recordati: significant sales and earnings growth in the first quarter 2013 (sales +11.4%, net income +11.8%) thanks to the international business (+16.1%) Recordati: significant sales and earnings growth in the first quarter 2013 (sales +11.4%, net income +11.8%) thanks to the international business (+16.1%) PDF, 574KB, opens in a new window
9 May 2013 Recordati: initiates a share buy-back program Recordati: initiates a share buy-back program PDF, 499KB, opens in a new window
7 May 2013 Recordati: Public disclosure compliance - Minutes SHGM 17.4.2013 Recordati: Public disclosure compliance - Minutes SHGM 17.4.2013 PDF, 398KB, opens in a new window
18 April 2013 Notice of 2012 final dividend payment Notice of 2012 final dividend payment PDF, 7KB, opens in a new window
17 April 2013 Recordati: shareholders approve the 2012 accounts. Dividend € 0.30 per share Recordati: shareholders approve the 2012 accounts. Dividend € 0.30 per share PDF, 1MB, opens in a new window
22 March 2013 Recordati: public disclosure compliance - Publication Remuneration report Recordati: public disclosure compliance - Publication Remuneration report PDF, 403KB, opens in a new window
15 March 2013 Shareholders' Meeting Call Notice Shareholders' Meeting Call Notice PDF, 138KB, opens in a new window
15 March 2013 Recordat: public disclosure compliance – Publications of the Directors’ reports Recordat: public disclosure compliance – Publications of the Directors’ reports PDF, 156KB, opens in a new window
14 March 2013 Recordati: Board approves a supplement to the agenda of the annual meeting of shareholders Recordati: Board approves a supplement to the agenda of the annual meeting of shareholders  PDF, 164KB, opens in a new window
14 March 2013 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 157KB, opens in a new window
8 March 2013 Notice of filing of the 2012 Annual Report Notice of filing of the 2012 Annual Report PDF, 50KB, opens in a new window
7 March 2013 Recordati: Board approves the 2012 accounts. Revenue € 828.3 million (+8.7%), operating income € 167.0 million (+2.1%), net income € 118.5 million (+1.8%). 2012 dividend € 0.30 Recordati: Board approves the 2012 accounts. Revenue € 828.3 million (+8.7%), operating income € 167.0 million (+2.1%), net income € 118.5 million (+1.8%). 2012 dividend € 0.30 PDF, 272KB, opens in a new window
12 February 2013 Recordati: positive preliminary 2012 results. Sales +8.7%, EBIT +2.1%, net income +1.8%. A productive year for investments Recordati: positive preliminary 2012 results. Sales +8.7%, EBIT +2.1%, net income +1.8%. A productive year for investments PDF, 527KB, opens in a new window
4 February 2013 Recordati to meet with the financial community and specialized press in Milan Recordati to meet with the financial community and specialized press in Milan PDF, 165KB, opens in a new window
21 January 2013 Recordati finalizes its acquisition of a portfolio of products in the USA Recordati finalizes its acquisition of a portfolio of products in the USA PDF, 352KB, opens in a new window
20 December 2012 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 159KB, opens in a new window
20 December 2012 Recordati: 2013 comporate events' calendar Recordati: 2013 comporate events' calendar PDF, 172KB, opens in a new window
23 November 2012 Recordati licenses Graspa® from Erytech in Europe Recordati licenses Graspa® from Erytech in Europe PDF, 205KB, opens in a new window
16 November 2012 Recordati finalizes its acquisition of a portfolio of products in Russia Recordati finalizes its acquisition of a portfolio of products in Russia PDF, 165KB, opens in a new window
26 October 2012 Notice of filing of financial report at 30 September 2012 Notice of filing of financial report at 30 September 2012 PDF, 78KB, opens in a new window
25 October 2012 Recordati: positive first nine months 2012 results (revenue +6.8%, net income +1.2%) thanks to the growth of the international business (+11.0%). Interim dividend € 0.20 per share Recordati: positive first nine months 2012 results (revenue +6.8%, net income +1.2%) thanks to the growth of the international business (+11.0%). Interim dividend € 0.20 per share PDF, 245KB, opens in a new window
16 October 2012 Recordati acquires a portfolio of products in Russia Recordati acquires a portfolio of products in Russia PDF, 121KB, opens in a new window
23 August 2012 Recordati finalizes its acquisition of Farma-Projekt in Poland Recordati finalizes its acquisition of Farma-Projekt in Poland PDF, 119KB, opens in a new window
2 August 2012 Recordati acquires the polish pharmaceutical company Farma-Projekt Recordati acquires the polish pharmaceutical company Farma-Projekt PDF, 120KB, opens in a new window
27 July 2012 Notice of filing of First Half 2012 financial report Notice of filing of First Half 2012 financial report PDF, 559KB, opens in a new window
26 July 2012 Recordati: positive first half 2012 results (revenue +4.7%, net income +1.5%) thanks to the growth of the international business (+9.1%) Recordati: positive first half 2012 results (revenue +4.7%, net income +1.5%) thanks to the growth of the international business (+9.1%)  PDF, 165KB, opens in a new window
21 May 2012 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 409KB, opens in a new window
8 May 2012 Recordati: good first quarter 2012 results (revenue +11.0%, net income +7.5%) thanks to the growth of the international business (+14.5%) Recordati: good first quarter 2012 results (revenue +11.0%, net income +7.5%) thanks to the growth of the international business (+14.5%) PDF, 187KB, opens in a new window
4 May 2012 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 138KB, opens in a new window
24 April 2012 Recordati acquires six OTC products in Germany Recordati acquires six OTC products in Germany PDF, 118KB, opens in a new window
19 April 2012 Recordati: shareholders approve the 2011 accounts. Dividend € 0.30 per share successfully Recordati: shareholders approve the 2011 accounts. Dividend € 0.30 per share successfully PDF, 157KB, opens in a new window
28 March 2012 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 139KB, opens in a new window
20 March 2012 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 419KB, opens in a new window
15 March 2012 Shareholders' Meeting Call Notice Shareholders' Meeting Call Notice PDF, 358KB, opens in a new window
7 March 2012 Recordati: Board approves the 2011 accounts. Revenue € 762.0 million (+4.7%), operating income € 163.5 million (+5.6%), net income € 116.4 million (+7.2%). 2011 dividend € 0.30 (+9.1%) Recordati: Board approves the 2011 accounts. Revenue € 762.0 million (+4.7%), operating income € 163.5 million (+5.6%), net income € 116.4 million (+7.2%). 2011 dividend € 0.30 (+9.1%) PDF, 175KB, opens in a new window
28 February 2012 Recordati: changes to the 2012 corporate events calendar Recordati: changes to the 2012 corporate events calendar PDF, 407KB, opens in a new window
9 February 2012 Recordati: positive preliminary 2011 results. Sales +4.7%, EBIT +5.6%, net income +7.2% Recordati: positive preliminary 2011 results. Sales +4.7%, EBIT +5.6%, net income +7.2% PDF, 147KB, opens in a new window
31 January 2012 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 400KB, opens in a new window
28 November 2011 Recordati: 2012 Corporate events' calendar Recordati: 2012 Corporate events' calendar PDF, 465KB, opens in a new window
18 November 2011 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 591KB, opens in a new window
15 November 2011 Notice of payment 2011 interim dividend Notice of payment 2011 interim dividend PDF, 76KB, opens in a new window
15 November 2011 Directors' report and financial statements interim dividend Directors' report and financial statements interim dividend PDF, 1.1MB, opens in a new window
14 November 2011 Recordati Board of Directors approves 2011 interim dividend of € 0.20 per share Recordati Board of Directors approves 2011 interim dividend of € 0.20 per share PDF, 120KB, opens in a new window
26 October 2011 Notice of filing of financial report at 30 September 2011 Notice of filing of financial report at 30 September 2011 PDF, 36KB, opens in a new window
25 October 2011 Very good first nine months 2011 results. Sales +5.8%. Net income +5.8% Interim dividend distribution policy approved Very good first nine months 2011 results. Sales +5.8%. Net income +5.8% Interim dividend distribution policy approved PDF, 171KB, opens in a new window
7 October 2011 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 213KB, opens in a new window
29 September 2011 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 740KB, opens in a new window
22 September 2011 Recordati initiates share buy-back program Recordati initiates share buy-back program PDF, 131KB, opens in a new window
14 September 2011 Recordati finalizes its acquisition of Frik İlaç in Turkey Recordati finalizes its acquisition of Frik İlaç in Turkey PDF, 121KB, opens in a new window
27 July 2011 Notice of filing of First Half 2011 financial report Notice of filing of First Half 2011 financial report PDF, 55KB, opens in a new window
26 July 2011 Recordati: very good first half 2011 results. Sales +6.6%. Net income +5.3% Recordati: very good first half 2011 results. Sales +6.6%. Net income +5.3% PDF, 182KB, opens in a new window
1 July 2011 Recordati acquires Dr. Frik İlaç in Turkey Recordati acquires Dr. Frik İlaç in Turkey PDF, 105KB, opens in a new window
31 May 2011 Recordati: approval granted for the use of Carbaglu® in the treatment of organic acidaemias Recordati: approval granted for the use of Carbaglu® in the treatment of organic acidaemias PDF, 43KB, opens in a new window
10 May 2011 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 203KB, opens in a new window
7 May 2011 Notice of filing of First quarter 2011 financial report Notice of filing of First quarter 2011 financial report PDF, 58KB, opens in a new window
6 May 2011 Recordati: sales and income increase in the first quarter 2011. Three year business plan updated Recordati: sales and income increase in the first quarter 2011. Three year business plan updated PDF, 65KB, opens in a new window
2 May 2011 Recordati announces the first European launch of pitavastain Recordati announces the first European launch of pitavastain PDF, 44KB, opens in a new window
27 April 2011 Recordati: to meet with the financial community and specialized press in Milan Recordati: to meet with the financial community and specialized press in Milan PDF, 42KB, opens in a new window
14 April 2011 Notice of dividend payment for the financial year 2010 Notice of dividend payment for the financial year 2010 PDF, 48KB, opens in a new window
13 April 2011 Recordati: shareholders approve the 2010 accounts, dividend € 0.275 per share Recordati: shareholders approve the 2010 accounts, dividend € 0.275 per share PDF, 65KB, opens in a new window
24 March 2011 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 214KB, opens in a new window
23 March 2011 Recordati: publication of the lists of candidates for the appointment of the Company's Directors of the Statutory Auditors Recordati: publication of the lists of candidates for the appointment of the Company's Directors of the Statutory Auditors PDF, 252KB, opens in a new window
20 March 2011 Recordati: information pursuant to art. 144-octies, paragraph 2 of issuers' regulations Recordati: information pursuant to art. 144-octies, paragraph 2 of issuers' regulations PDF, 255KB, opens in a new window
18 March 2011 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 50KB, opens in a new window
14 March 2011 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 214KB, opens in a new window
10 March 2011 Recordati: publication of 2010 Annual Report and Annual Report on Corporate Governance Recordati: publication of 2010 Annual Report and Annual Report on Corporate Governance PDF, 33KB, opens in a new window
10 March 2011 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 215KB, opens in a new window
9 March 2011 Recordati: 2010 accounts approved by the Board. Net income € 108.6 million. Dividend per share € 0.275 Recordati: 2010 accounts approved by the Board. Net income € 108.6 million. Dividend per share € 0.275 PDF, 75KB, opens in a new window
3 March 2011 Recordati: update on the execution of the share buy-back program Recordati: update on the execution of the share buy-back program PDF, 54KB, opens in a new window
2 March 2011 Recordati: notice to convene an ordinary and extraordinary meeting of the shareholders Recordati: notice to convene an ordinary and extraordinary meeting of the shareholders PDF, 74KB, opens in a new window
23 February 2011 Recordati: update on the execution of the share buy back program Recordati: update on the execution of the share buy back program PDF, 221KB, opens in a new window
15 February 2011 Recordati initiates share buy-back program Recordati initiates share buy-back program PDF, 290KB, opens in a new window
10 February 2011 Recordati: change to the corporate events calendar 2011 Recordati: change to the corporate events calendar 2011 PDF, 34KB, opens in a new window
9 February 2011 Recordati: preliminary full year 2010 results: revenues € 728.1 M. net income € 108.6 M. Profitability margins in line with 2009 Recordati: preliminary full year 2010 results: revenues € 728.1 M. net income € 108.6 M. Profitability margins in line with 2009 PDF, 132KB, opens in a new window
19 January 2011 Recordati acquires Procto-Glyvenol® for the Central and Eastern European markets Recordati acquires Procto-Glyvenol® for the Central and Eastern European markets PDF, 30KB, opens in a new window
23 December 2010 Recordati signs co-marketing agreement with Merck Serono in France for pitavastatin Recordati signs co-marketing agreement with Merck Serono in France for pitavastatin PDF, 46KB, opens in a new window
23 December 2010 Recordati in-licenses Cardicor® in Italy from Merck KGaA Recordati in-licenses Cardicor® in Italy from Merck KGaA PDF, 43KB, opens in a new window
16 December 2010 Recordati and Nymox Pharmaceutical Corporation announce European licensing agreement for NX-1207 Recordati and Nymox Pharmaceutical Corporation announce European licensing agreement for NX-1207 PDF, 44KB, opens in a new window
15 December 2010 Recordati: public disclosure compliance Recordati: public disclosure compliance PDF, 23KB, opens in a new window
28 October 2010 Recordati: minutes of the Board meeting published which amended the by-laws to comply with new regulations on shareholder rights Recordati: minutes of the Board meeting published which amended the by-laws to comply with new regulations on shareholder rights PDF, 54KB, opens in a new window
26 October 2010 Notice of filing of financial report at 30 September 2010 Notice of filing of financial report at 30 September 2010 PDF, 13KB, opens in a new window
26 October 2010 Recordati: positive first nine months 2010 results, EBIT and net income increase Recordati: positive first nine months 2010 results, EBIT and net income increase PDF, 68KB, opens in a new window
28 August 2010 The sixth edition of the Arrigo Recordati International Prize for Scientific Research issues the Call for Nominations The sixth edition of the Arrigo Recordati International Prize for Scientific Research issues the Call for Nominations PDF, 441KB, opens in a new window
29 July 2010 Notice of filing of First Half 2010 financial report Notice of filing of First Half 2010 financial report PDF, 14KB, opens in a new window
28 July 2010 Recordati: positive first half 2010 results, EBIT and net income increase Recordati: positive first half 2010 results, EBIT and net income increase PDF, 247KB, opens in a new window
15 July 2010 Recordati: positive conclusion to the Decentralized Procedure for the approval in Europe of pitavastatin (Livazo®) Recordati: positive conclusion to the Decentralized Procedure for the approval in Europe of pitavastatin (Livazo®) PDF, 44KB, opens in a new window
8 June 2010 Recordati enters the Romanian market Recordati enters the Romanian market PDF, 30KB, opens in a new window
7 May 2010 Recordati signs an agreement with Zambon for the co-marketing of silodosin in France Recordati signs an agreement with Zambon for the co-marketing of silodosin in France PDF, 97KB, opens in a new window
6 May 2010 Recordati: positive first quarter 2010 results, sales and income increase. Three year business plan updated Recordati: positive first quarter 2010 results, sales and income increase. Three year business plan updated PDF, 68KB, opens in a new window
27 April 2010 Recordati to meet with the financial community and specialized press in Milan Recordati to meet with the financial community and specialized press in Milan PDF, 29KB, opens in a new window
13 April 2010 Dividend payment for the financial year 2009
13 April 2010 Recordati: shareholders approve the 2009 accounts. Dividend € 0.275 per share (+10.0%) Recordati:  shareholders approve the 2009 accounts.  Dividend € 0.275 per share  (+10.0%) PDF, 61KB, opens in a new window
7 April 2010 Recordati signs co-marketing agreement with Esteve in Spain for pitavastatin Recordati signs co-marketing agreement with Esteve in Spain for pitavastatin PDF, 43KB, opens in a new window
26 March 2010 Recordati: documents of the annual Shareholders'meeting of 13th April 2010 (1st call) and 16th April 2010 (2nd call) Recordati: documents of the annual Shareholders'meeting of 13th April 2010 (1st call) and 16th April 2010 (2nd call) PDF, 21KB, opens in a new window
19 March 2010 Recordati: Carbaglu® approved by the FDA for use in the U.S.A. Recordati: Carbaglu® approved by the FDA for use in the U.S.A. PDF, 43KB, opens in a new window
15 March 2010 Recordati and Leespharm announce partnership for Zanidip® in China Recordati and Leespharm announce partnership for Zanidip® in China PDF, 46KB, opens in a new window
11 March 2010 Notice of Annual Shareholders' Meeting to be held on 13 April 2010 Notice of Annual Shareholders' Meeting to be held on 13 April 2010 PDF, 245KB, opens in a new window
5 March 2010 Recordati: 2009 accounts approved by the board. Net income € 110.6 million. Dividend per share € 0.275 (+10%) Recordati: 2009 accounts approved by the board. Net income € 110.6 million. Dividend per share € 0.275 (+10%) PDF, 73KB, opens in a new window
11 February 2010 Recordati: preliminary full year 2009 results in line with targets: revenues +8.4%, net income +10.1% Recordati: preliminary full year 2009 results in line with targets: revenues +8.4%, net income +10.1% PDF, 53KB, opens in a new window
3 February 2010 Recordati: silodosin (Urorec®/Silodyx™) approved by the European Commission for the treatment of the signs and symptoms of BPH Recordati: silodosin (Urorec®/Silodyx™) approved by the European Commission for the treatment of the signs and symptoms of BPH PDF, 94KB, opens in a new window
20 November 2009 Recordati: EMEA/CHMP adopts a positive opinion for silodosin (brands Urorec® and Silodyx™) Recordati: EMEA/CHMP adopts a positive opinion for silodosin (brands Urorec® and Silodyx™) PDF, 77KB, opens in a new window
27 October 2009 Recordati: positive first nine months 2009 results, sales and income increase Recordati: positive first nine months 2009 results, sales and income increase PDF, 85KB, opens in a new window
29 July 2009 Recordati signs a license agreement with Pharmaplan for silodosin in South Africa Recordati signs a license agreement with Pharmaplan for silodosin in South Africa PDF, 71KB, opens in a new window
29 July 2009 Recordati signs an agreement with Nycomed for the co-marketing of silodosin in Italy
28 July 2009 Recordati: positive first half 2009 results, sales and income increase Recordati: positive first half 2009 results, sales and income increase PDF, 90KB, opens in a new window
14 July 2009 Recordati announces revenues up 8.9% in the first half 2009 Recordati announces revenues up 8.9% in the first half 2009 PDF, 64KB, opens in a new window
13 July 2009 Recordati obtains TransAct LAT® license from Amdipharm Recordati obtains TransAct LAT® license from Amdipharm PDF, 49KB, opens in a new window
6 May 2009 Recordati: positive first quarter 2009 results Recordati: positive first quarter 2009 results PDF, 90KB, opens in a new window
15 April 2009 Recordati launches Zanextra® in France Recordati launches Zanextra® in France PDF, 72KB, opens in a new window
7 April 2009 Recordati: shareholders approve the 2008 accounts. Dividend € 0,25 per share (+16.3%) Recordati: shareholders approve the 2008 accounts. Dividend € 0,25 per share (+16.3%) PDF, 86KB, opens in a new window
3 April 2009 Recordati signs co-marketing agreement with Almirall in Spain for silodosin Recordati signs co-marketing agreement with Almirall in Spain for silodosin PDF, 71KB, opens in a new window
3 March 2009 Recordati: 2008 accounts approved by the board. Net income +18.3%. Dividend per share € 0.25 Recordati: 2008 accounts approved by the board. Net income +18.3%. Dividend per share € 0.25 PDF, 56KB, opens in a new window
11 February 2009 Recordati: preliminary full year 2008 results in line with targets: revenues +9.7%, net income +18.3% Recordati: preliminary full year 2008 results in line with targets: revenues +9.7%, net income +18.3% PDF, 32KB, opens in a new window
19 January 2009 Recordati acquires Herbaco-Bofarma in the Czech Republic Recordati acquires Herbaco-Bofarma in the Czech Republic PDF, 43KB, opens in a new window
Get adobe reader

Most computers will open PDF documents automatically, but you may need to download Adobe Reader.

Last updated on:
29/07/14
10:56:21 CET
Delivered by Investis (opens in a new window)